SEARCH

SEARCH BY CITATION

References

  • Alam Z. I., Daniel S. E., Lees A. J., Marsden D. C., Jenner P. and Halliwell B. (1997) A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J. Neurochem. 69, 13261329.
  • Bennett M. C., Bishop J. F., Leng Y., Chock P. B., Chase T. N. and Mouradian M. M. (1999) Degradation of α-synuclein by proteasome. J. Biol. Chem 274, 3385533858.
  • Canu N., Barbato C., Ciotti M. T., Serafino A., Dus L. and Calissano P. (2000) Proteasome involvement and accumulation of ubiquitinated proteins in cerebellar granule neurons undergoing apoptosis. J. Neurosci. 20, 589599.
  • Casper D., Mytilineou C. and Blum M. (1991) EGF enhances the survival of dopamine neurons in rat embryonic mesencephalon primary cell culture. J. Neurosci. Res. 30, 372381.
  • Craiu A., Gaczynska M., Akopian T., Gramm C. F., Fenteany G., Goldberg A. L. and Rock K. L. (1997) Lactacystin and clasto-lacta-cystin β-lactone modify multiple proteasome β-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J. Biol. Chem. 272, 1343713445.
  • Davies K. J. (2001) Degradation of oxidized proteins by the 20S proteasome. Biochimie 83, 301310.
  • Fenteany G. and Schreiber S. L. (1998) Lactacystin, proteasome function, and cell fate. J. Biol. Chem. 273, 85458548.
  • Forno L. S. (1996) Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 55, 259272.
  • Giasson B. I., Duda J. E., Murray I. V., Chen Q., Souza J. M., Hurtig H. I., Ischiropoulos H., Trojanowski J. Q. and Lee V. M. (2000) Oxidative damage linked to neurodegeneration by selective α-syn-uclein nitration in synucleinopathy lesions. Science 290, 985989.
  • Goedert M. (2001) Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2, 492501.DOI: 10.1038/35081564
  • Good P. F., Hsu A., Werner P., Perl D. P. and Olanow C. W. (1998) Protein nitration in Parkinson's disease. J. Neuropathol. Exp. Neurol. 57, 338342.
  • Hirsch E. C., Faucheux B., Damier P., Mouatt-Prigent A. and Agid Y. (1997) Neuronal vulnerability in Parkinson's disease. J. Neural Transm. 50, 7988.
  • Jenner P. and Olanow C. W. (1998) Understanding cell death in Parkinson's disease. Ann. Neurol. 44, S72S84.
  • Lee M., Hyun D., Halliwell B. and Jenner P. (2001) Effect of the overexpression of wild-type or mutant α-synuclein on cell susceptibility to insult. J. Neurochem. 76, 9981009.
  • Leroy E., Boyer R., Auburger G., Leube B., Ulm G., Mezey E., Harta G., Brownstein M. J., Jonnalagada S., Chernova T., Dehejia A., Lavedan C., Gasser T., Steinbach P. J., Wilkinson K. D. and Polymeropoulos M. H. (1998) The ubiquitin pathway in Parkinson's disease. Nature 395, 451452.
  • Lopiano L., Fasano M., Giraudo S., Digilio G., Koenig S. H., Torre E., Bergamasco B. and Aime S. (2000) Nuclear magnetic relaxation dispersion profiles of substantia nigra pars compacta in Parkinson's disease patients are consistent with protein aggregation. Neurochem. Int. 37, 331336.
  • McNaught K. S. and Jenner P. (1999) Altered glial function causes neuronal death and increases neuronal susceptibility to 1-methyl-4-phenylpyridinium- and 6-hydroxydopamine-induced toxicity in astrocytic/ventral mesencephalic co-cultures. J. Neurochem. 73, 24692476.DOI: 10.1046/j.1471-4159.1999.0732469.x
  • McNaught K. S. and Jenner P. (2001) Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci. Lett. 297, 191194.
  • McNaught K. S., Olanow C. W., Halliwell B., Isacson O. and Jenner P. (2001) Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat. Rev. Neurosci. 2, 589594.DOI: 10.1038/35086067
  • McNaught K. St P., Belizaire R., Jenner P., Olanow C. W. and Isacson O. (2002) Selective loss of 20S proteasome α-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci. Lett. (in press).
  • Melandri F., Grenier L., Plamondon L., Huskey W. P. and Stein R. L. (1996) Kinetic studies on the inhibition of isopeptidase T by ubiquitin aldehyde. Biochemistry 35, 1289312900.
  • Mezey E., Dehejia A. M., Harta G., Tresser N., Suchy S. F., Nussbaum R. L., Brownstein M. J. and Polymeropoulos M. H. (1998) α-Synuclein is present in Lewy bodies in sporadic Parkinson's disease. Mol. Psychiatry 3, 493499.
  • Pardo B., Paino C. L., Casarejos M. J. and Mena M. A. (1997) Neuronal-enriched cultures from embryonic rat ventral mesencephalon for pharmacological studies of dopamine neurons. Brain Res. Brain Res. Protoc. 1, 127132.
  • Pollanen M. S., Dickson D. W. and Bergeron C. (1993) Pathology and biology of the Lewy body. J. Neuropathol. Exp. Neurol. 52, 183191.
  • Polymeropoulos M. H., Lavedan C., Leroy E., Ide S. E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E. S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W. G., Lazzarini A. M., Duvoisin R. C., Di Iorio G., Golbe L. I. and Nussbaum R. L. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 20452047.
  • Rideout H. J., Larsen K. E., Sulzer D. and Stefanis L. (2001) Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells. J. Neurochem. 78, 899908.
  • Saigoh K., Wang Y. L., Suh J. G., Yamanishi T., Sakai Y., Kiyosawa H., Harada T., Ichihara N., Wakana S., Kikuchi T. and Wada K. (1999) Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat. Genet. 23, 4751.
  • Schaeffer J. R. and Cohen R. E. (1996) Differential effects of ubiquitin aldehyde on ubiquitin and ATP-dependent protein degradation. Biochemistry 35, 1088610893.
  • Sherman M. Y. and Goldberg A. L. (2001) Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 29, 1532.
  • Shimura H., Hattori N., Kubo S., Yoshikawa M., Kitada T., Matsumine H., Asakawa S., Minoshima S., Yamamura Y., Shimizu N. and Mizuno Y. (1999) Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients. Ann. Neurol. 45, 668672.DOI: 10.1002/1531-8249(199905)45:5<668::AID-ANA19>3.0.CO;2-Z
  • Shimura H., Schlossmacher M. G., Hattori N., Frosch M. P., Trockenbacher A., Schneider R., Mizuno Y., Kosik K. S. and Selkoe D. J. (2001) Ubiquitination of a new form of (α)-synuclein by Parkin from human brain: implications for Parkinson's disease. Science 28, 28.
  • Spillantini M. G., Crowther R. A., Jakes R., Hasegawa M. and Goedert M. (1998) α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. USA 95, 64696473.
  • Spira P. J., Sharpe D. M., Halliday G., Cavanagh J. and Nicholson G. A. (2001) Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr α-synuclein mutation. Ann. Neurol. 49, 313319.
  • Stefanis L., Larsen K. E., Rideout H. J., Sulzer D. and Greene L. A. (2001) Expression of A53T mutant but not wild-type α-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J. Neurosci. 21, 95499560.
  • Tanaka Y., Engelender S., Igarashi S., Rao R. K., Wanner T., Tanzi R. E., Sawa A. V. L. D., Dawson T. M. and Ross C. A. (2001) Inducible expression of mutant α-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum. Mol. Genet. 10, 919926.
  • Tofaris G. K., Layfield R. and Spillantini M. G. (2001) α-Synuclein metabolism and aggregation is linged to ubiqutin-independent degradation by the proteasome. FEBS Lett. 25504, 15.
  • Yoritaka A., Hattori N., Uchida K., Tanaka M., Stadtman E. R. and Mizuno Y. (1996) Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc. Natl. Acad. Sci. USA 93, 26962701.